COMP <GO>
XRAY vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
DENTSPLY SIRONA Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: XRAY 3
— MRK 8
■ METRIC PARITY
LAST: $9.53 (-0.83%) • MKT CAP: $1.92B
options-implied-move
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XRAY VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XRAY | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.00% | 74.80% | -24.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.00% | 20.70% | -31.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 12.27% | 3.42% | +8.85 | XRAY | /fcf-yield <GO> |
| Operating Margin | -11.50% | 34.30% | -45.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | -16.20% | 28.10% | -44.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 1.30% | -4.30 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 6.68% | 2.26% | +4.42 | XRAY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.19 | -4.74 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.5 | 51.7 | +4.80 | XRAY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.92B | $361.02B | -$359.11B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XRAY REV | MRK REV | XRAY GROSS % | MRK GROSS % | XRAY FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.68B | $65.01B | 50.0% | 74.8% | $235.0M | $12.36B |
| FY 2024 | $3.79B | $64.17B | 51.6% | 76.3% | $461.0M | $18.10B |
| FY 2023 | $3.96B | $60.12B | — | — | $377.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XRAY // BETA —
MRK // BETA 0.92